195 related articles for article (PubMed ID: 26622603)
1. Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review.
Wang SB; Lei KJ; Liu JP; Jia YM
Oncol Lett; 2015 Aug; 10(2):954-956. PubMed ID: 26622603
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib induced trichomegaly of the eyelashes.
Jeon SH; Ryu JS; Choi GS; Kim JS; Kwon HY; Kim MS; Nam HS; Cho JH; Kwak SM; Lee HL; Kim HJ; Hong GJ
Tuberc Respir Dis (Seoul); 2013 Jan; 74(1):37-40. PubMed ID: 23390452
[TBL] [Abstract][Full Text] [Related]
3. Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review.
Zheng H; Zhang H; Zhang T; Wang Q; Hu F; Li B
Exp Ther Med; 2016 Sep; 12(3):1287-1292. PubMed ID: 27588051
[TBL] [Abstract][Full Text] [Related]
4. Ocular side effects and trichomegaly of eyelashes induced by erlotinib: a case report and review of the literature.
Celik T; Kosker M
Cont Lens Anterior Eye; 2015 Feb; 38(1):59-60. PubMed ID: 25249292
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors.
Cohen PR; Escudier SM; Kurzrock R
Am J Clin Dermatol; 2011 Feb; 12(1):63-7. PubMed ID: 20726623
[TBL] [Abstract][Full Text] [Related]
8. Eyelash trichomegaly: a systematic review of acquired and congenital aetiologies of lengthened lashes.
Hutchison DM; Duffens A; Yale K; Park A; Cardenas K; Mesinkovska NA
J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):536-546. PubMed ID: 34919300
[TBL] [Abstract][Full Text] [Related]
9. A case of acquired trichomegaly following treatment with erlotinib.
Jazayeri F; Malhotra R
BMJ Case Rep; 2009; 2009():. PubMed ID: 21687012
[TBL] [Abstract][Full Text] [Related]
10. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
Zhai H; Zhong W; Yang X; Wu YL
Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
[TBL] [Abstract][Full Text] [Related]
13. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
14. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis.
Batson S; Mitchell SA; Windisch R; Damonte E; Munk VC; Reguart N
Onco Targets Ther; 2017; 10():2473-2482. PubMed ID: 28503070
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine Kinase Inhibitors in the Treatment of Choroidal Metastases from Non-Small-Cell Lung Cancer: A Case Report and Review of Literature.
Nair AG; Asnani HT; Mehta VC; Mehta SV; Pathak RS; Palkar AH; Gopinathan I
Ocul Oncol Pathol; 2017 Jan; 3(1):28-33. PubMed ID: 28275600
[TBL] [Abstract][Full Text] [Related]
18. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
19. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Kashima J; Okuma Y; Miwa M; Hosomi Y
Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
